Pharmacyclics
Kathi Cohen, CAP-OM, has extensive experience in administrative support and management within the pharmaceutical and healthcare industries. Currently serving as Executive Assistant to the Regulatory Affairs Therapeutic Area Head and Global Development Lead for Imbruvica and Pediatrics at Pharmacyclics, an AbbVie Company, since March 2013, Kathi provides comprehensive support including calendar management, FDA meeting logistics, and departmental budget management. Kathi has also held positions as Executive Assistant in various organizations including DaVita, Honeywell, and Zend Technologies, showcasing a strong track record in executive assistance and project management. In addition to practical experience, Kathi has also contributed to the International Association of Administrative Professionals as Chapter President and Treasurer. Educational credentials include certifications in Executive Assistance and Bookkeeping from the University of California, Santa Cruz.
This person is not in any teams
This person is not in any offices
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.